British fertility society policy and practice committee: Prevention of ovarian hyperstimulation syndrome

Human Fertility

Volumn 17, Issue 4, 2014, Pages 257-268

  Mathur, R S ^a   Tan, B K ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHORIONIC GONADOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; HETASTARCH; METFORMIN; RECOMBINANT LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR;

ARTICLE; CORPUS LUTEUM; CRYOPRESERVATION; DIATHERMY; FEMALE; FOLLICULAR ASPIRATION; HUMAN; IN VITRO FERTILIZATION; INFERTILITY THERAPY; LAPAROSCOPIC OVARIAN DIATHERMY; MEDICAL SOCIETY; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; OVULATION INDUCTION; POLICY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADVERSE EFFECTS; BLOOD; MALE; OVARIAN HYPERSTIMULATION SYNDROME; PROCEDURES; RISK FACTOR;

ANTI-MULLERIAN HORMONE; CHORIONIC GONADOTROPIN; FEMALE; HUMANS; MALE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; RISK FACTORS;

EID: 84938054750     PISSN: 14647273     EISSN: 17428149     Source Type: Journal    
DOI: 10.3109/14647273.2014.961745     Document Type: Article

References (91)

1. Abdalla, H.I., Ah-Moye, M., Brinsden, P., Howe, D.L., Okonofua, F., & Craft, I. (1987). The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertility and Sterility, 48, 958–963.
2. Abdalla, S. & Nicopoullos, J. (2010). The effect of duration of coasting and estradiol drop on the outcome of assisted reproduction: 13 years of experience in 1,068 coasted cycles to prevent ovarian Hyperstimulation. Fertility and Sterility, 94, 1757–1763.
3. Al-Inany, H.G., Youssef, M.A., Aboulghar, M., Broekmans, F.J., Sterrenburg, M.D., Smit, J.G., & Abou-Setta, A.M. (2011). Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews, 5, Art. No.: CD001750. doi:10.1002/14651858.CD001750.pub3.
4. Alvarez, C., Marti-Bonmati, L., Novella-Maestre, E., Sanz, R., Gomez, R., Fernandez-Sanchez, M., et al. (2007a). Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism, 92, 2931–2937
5. Alvarez, C., Alonso-Muriel, I., Garc ı a, G., Crespo, J., Bellver, J., Simon, C., & Pellicer, A. (2007b). Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study Human Reproduction, 22, 3210–3214.
6. Asch, R.H., Li, H.P., Balmaceda, J.P., Weckstein, L.N., & Stone, S.C. (1991). Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Human Reproduction, 6, 1395–1399.
7. Asch, R.H., Ivery, G., Goldsman, M., Frederick, J.L., Stone, S.C., & Balmaceda, J.P. (1993). The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Human Reproduction, 8, 1015–1020.
8. Babayof, R., Margalioth, E.J., Huleihel, M., Amash, A., Zylber- Haran, E., Gal, M., et al. (2006). Serum Inhibin A, VEGF and TNFa levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction, 21, 1260–1265.
9. Bayram, N., van Wely, M., & van der Veen, F. (2001). Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. The Cochrane Database of Systematic Reviews, 2, CD002121
10. Benavida, C.A., Davis, O., Kligman I., Moomjy, M., Liu, H.C., & Rosenwaks, Z. (1997). Withholding gonadotrophin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertility and Sterility, 67, 724–727.
11. Balasch, J., F á bregues, F., Creus, M., Puerto, B., Peñarrubia, J., & Vanrell, J.A. (2001). Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose stepup and modified step-down regimens. Human Reproduction, 16, 652–656.
12. Bellver, J., Muñoz, E.A., Ballesteros, A., Soares, S.R., Bosch, E., Simón, C., et al. (2003). Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in highrisk IVF patients: a randomized controlled study. Human Reproduction, 18, 2283–2288.
13. Blankstein, J., Shalev, J., Saadon, T., Kukia, E.E., Rabinovici, J., Pariente, C., et al. (1987). Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertility and Sterility, 47, 597–602.
14. Carizza, C., Abdelmassih, V., Abdelmassih, S., Ravizzini, P., Salgueiro, L., Salgueiro, P.T., et al. (2008). Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive BioMedicine Online, 17, 751–755
15. Chang, P., Kenley, S., Burns, T., Denton, G., Currie, K., DeVane, G., & O ’Dea, L. (2001). Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. Fertility and Sterility, 76, 67–74.
16. Christin-Maitre, S. & Hugues, J.N. (2003). A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Human Reproduction, 18, 1626–1631.
17. Chun, S., Eisenhauer, K., Minami, S., Billig, H., Perlas, E., & Hsueh, A. (1996). Hormonal regulation of apoptosis in early astral follicles: follicle-stimulating hormone as a major survival factor. Endocrinology, 137, 1447–1456.
18. D ’Angelo, A. & Amso, N.N. (2002). Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Human Reproduction, 17, 2787–2794.
19. D ’Angelo, A. (2010). Ovarian hyperstimulation syndrome prevention strategies: cryopreservation of all embryos. Seminars in Reproductive Medicine, 28, 513–518.
20. D ’Angelo, A., Brown, J., & Amso, N.N. (2011). Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 6, Art. No.: CD002811. doi:10.1002/14651858.CD002811.pub3.
21. Delvigne, A., Demoulin, A., Smitz, J., Donnez, J., Koninckx, P., Dhont, M., et al. (1993). The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Human Reproduction, 8, 1353–1360.
22. Delvigne, A., Vandromme, J., Demeestere, I. & Leroy, F. (1997) Unpredictable cases of complicated ovarian hyperstimulation in IVF. International Journal of Fertility and Women ’ s Medicine, 42, 268–270.
23. Delvigne, A. & Rozenberg, S. (2001). Preventive attitude of physicians to avoid OHSS in IVF patients. Human Reproduction, 16, 2491–2495.
24. Delvigne, A. & Rozenberg, S. (2002a). Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update, 8, 559–577.
25. Delvigne, A. & Rozenberg, S. (2002b). A systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in in vitro fertilisation patients. Human Reproduction Update, 8, 291–296.
26. de Ziegler, D., Streuli, I., Gayet, V., Frydman, N., Bajouh, O., & Chapron, C. (2012). Retrieving oocytes from small nonstimulated follicles in polycystic ovary syndrome (PCOS): in vitro maturation (IVM) is not indicated in the new GnRH antagonist era. Fertility and Sterility, 98, 290–293.
27. Dhont, M., Van der Straeten, F., & De Sutter, P. (1998). Prevention of severe ovarian hyperstimulation by coasting. Fertility and Sterility, 70, 847–850.
28. Doldi, N., Persico, P., Di Sebastiano, F., Marsiglio, E., & Ferrari, A. (2006) Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology, 22, 235–238.
29. Doronzo, G., Russo, I., Mattiello, L., Anfossi G., Bosia, A., & Trovati, M. (2004). Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: infl uence of nitric oxide and of insulin resistance. European Journal of Clinical Investigation, 34, 664–673.
30. Egbase, P.E., Makhseed, M., Al Sharhan, M., & Grudzinskas, J.G. (1997). Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Human Reproduction, 12, 2603–2606.
31. Egbase, P.E., Sharhan, M.A., & Grudzinskas, J.G. (1999). Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Human Reproduction, 14, 2922–2923.
32. Endo, T., Honnma, H., Hayashi, T., Chida, M., Yamazaki, K., Kitajima, Y., et al. (2002). Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian Hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Human Reproduction, 17, 2548–2551.
33. Engmann L, DiLuigi, A., Schmidt, D., Nulsen, J., Maier, D., & Benadiva, C. (2008). The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian Hyperstimulation syndrome: a prospective randomised controlled study. Fertility and Sterility, 89, 84–91.
34. Enskog, A., Henriksson, M., Unander, M., Nilsson, L., & Brannstrom, M. (1999). Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility, 71, 808–814.
35. Ferraretti, A.P., Gianaroli, L., Magli, C., Fortini, D., Selman, H.A., & Feliciani, E. (1999). Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Human Reproduction, 14, 1457–1460.
36. García-Velasco, J.A., Isaza, V., Quea, G., & Pellicer, A. (2006). Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertility and Sterility, 85, 547–554.
37. Gokmen, O., Ugur, M., Ekin, M., Keles, G., Turan, C., & Oral, H. (2001). Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 96, 187–192.
38. Graf, M.A., Fischer, R., Naether, O.G., Baukloh, V., Tafel, J., & Nuckel, M. (1997). Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. Human Reproduction, 12, 2599–2602.
39. Gremeau, A.S., Andreadis, N., Fatum, M., Craig, J., Turner, K., McVeigh, E., & Child, T. (2012). In vitro maturation or in vitro fertilization for women with polycystic ovaries? A casecontrol study of 194 treatment cycles. Fertility and Sterility, 98, 355–360
40. Homburg, R. & Howles, C.M. (1999). Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rational, results, refl ections refinements. Human Reproduction Update, 5, 493–499.
41. Humaidan, P., Kol, S., Papanikolaou, E.G. on behalf of ‘ The Copenhagen GnRH Agonist Triggering Workshop Group. (2011). GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Human Reproduction Update, 17, 510–524.
42. Humaidan, P., Papanikolaou, E.G., Kyrou, D., Alsbjerg, B., Polyzos, N.P., Devroey, P., & Fatemi, H.M. (2012). The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reproductive BioMedicine Online, 24, 134–141.
43. Humaidan, P., Bredkjaer, H.E., Westergaard, L.G., & Andersen, C.Y., (2010). 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropinreleasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertility and Sterility, 93, 847–854.
44. Iliodromiti, S., Blockeel, C., Tremellen, K.P., Fleming, R., Tournaye, H., Humaidan, P., & Nelson, S.M. (2013). Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Human Reproduction, 28, 2529–2536.
45. Jayaprakasan, K., Chan, Y., Islam, R., Haoula, Z., Hopkisson, J., Coomaraswami, A., & Raine-Fenning, N. (2012). Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertility and Sterility, 98, 657–663.
46. Kamath, M.S., Mangalraj, A.M., Muthukumar, K.M., & George, K. (2008). Gonadotrophin releasing hormone antagonist in IVF/ ICSI. Journal of Human Reproductive Sciences, 1, 29–32.
47. Klemetti, R., Sevon, T., Gissler, M., & Hemminki, E. (2005). Complications of IVF and ovulation induction. Human Reproduction, 20, 3293–3300.
48. K ö nig, E., Bussen, S., Sutterlin, M., & Steck, T. (1998). Prophylactic intravenous hydroxyethyl starch solution prevents moderatesevere ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Human Reproduction, 13, 2421–2424.
49. Kwee, J., Elting, M.W., Schats, R., McDonnell, J., & Lambalk, C.B.. (2007). Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Human Reproduction, 15, 5–9.
50. La Marca, A., Giulini, S., Tirelli, A., Bertucci, E., Marsella, T., Xella, S., & Volpe, A. (2007). Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Human Reproduction, 22, 766–771.
51. Lee, T-H., Chung-Hsien, L., Huang, C-C., Wu, Y-L., Shih, Y-T., Ho, H-N., Yang, Y-S., & Lee, M-S. (2008). Serum antimüllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles Human Reproduction, 23, 160–167.
52. van der Linden, M., Buckingham, K., Farquhar, C., Kremer, J.A.M., & Metwally, M. (2011). Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD009154. doi:10.1002/14651858. CD009154.pub2
53. Marci, R., Senn, A., Dessole, S., Chanson, A., Loumaye, E., Grandi, P., & Germond, M. (2001). A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertility and Sterility, 76, 1131–1135.
54. Mathur, R.S., Joels, L.A., & Jenkins, J.M. (1995). Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Acta Geneticae Medicae et Gemellologiae, 44, 233–235.
55. Mathur, R.S., Akande, A.V., Keay, S.D., Hunt, L.P., & Jenkins, J.M. (2000). Distinction between early and late ovarian hyperstimulation syndrome. Fertility and Sterility, 73, 901–907.
56. Mathur, R., Hayman, G., Bansal, A., & Jenkins, J. (2002). Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertility and Sterility, 78, 1154–1158.
57. Matorras, R., Andr é s, M., Mendoza, R., Prieto, B., Pijoan, J.I., & Expósito, A. (2013). Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics, Gynecology and Reproductive Biology, 8. pii: S0301-2115(13)00317-5. doi:10.1016/j.ejogrb.2013.07.010. [Epub ahead of print]
58. Merviel, P., Najas, S., Campy, H., Floret, S., & Brasseur, F. (2005). Use of GNRH antagonists in reproductive medicine. Minerva Ginecologica, 57, 29–43.
59. Nardo, L.G., Gelbaya, T.A., Wilkinson, H., Roberts, S.A., Yates, A., Pemberton, P., & Laing, I. (2009). Circulating basal anti- Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertility and Sterility, 92, 1586–1593.
60. Mansour, R., Aboulghar, M., Serour, G., Amin, Y., & Abou-Setta, A.M. (2005). Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction, 20, 3167–3172.
61. Nargund, G., Hutchison, L., Scaramuzzi, R., & Campbell, S. (2007). Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reproductive BioMedicine Online, 14, 682–685.
62. Navot, D., Bergh, P.A., & Laufer, N. (1992). Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility, 58, 249–261.
63. Nelson, S.M., Yates, R.W., Lyall, H., Jamieson, M., Traynor, I., Gaudoin, M., et al. (2009.) Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Human Reproduction, 24, 867–875.
64. Nugent, D., Vandekerckhove, P., Hughes, E., Arno, M., & Lilford, R. (2000). Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome (Review). Cochrane Database of Systematic Reviews, 3, Art. No.: CD000410. doi:10.1002/14651858.CD000410.
65. Orvieto, R. (2005). Can we eliminate severe ovarian hyperstimulation syndrome? Human Reproduction, 20, 320–322.
66. Papanikolaou, E.G., Pozzobon, C., Kolibianakis, E.M., Camus, M., Tournaye, H., Fatemi, H.M., et al. (2006). Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertility and Sterility, 85, 112–120.
67. Papanikolaou, E.G., Verpoest, W., Fatemi, H., Tarlatzis, B., Devroey, P., & Tournaye, H. (2011). A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertility and Sterility, 95, 1174–1177.
68. Peitsidis, P. & Agrawal, R. (2010). Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. Reproductive BioMedicine Online, 20, 444–452.
69. Pirard, C., Donnez, J., & Loumaye, E. (2006). GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Human Reproduction, 21, 1894–1900.
70. Pundir, J., Sunkara, S.K., El-Toukhy, T., & Khalaf, Y. (2011). Metaanalysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reproductive BioMedicine Online, 24, 6–22.
71. Rimington, M.R., Walker, S.M., & Shaw, R.W. (1997). The use of laparoscopic ovarian electrocautery in preventing cancellation of invitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Human Reproduction, 12, 1443–1447.
72. Schwarzler, P., Abendstein, B.J., Klingler, A., Kreuzer, E., & Rjosk, H.-K. (2003). Prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF patients by steroidal ovarian suppression–a prospective randomized study. Human Fertility, 6, 125–129.
73. Seyhan, A., Ata, B., Polat, M., Son, W.Y., Yarali, H., & Dahan, M.H. (2013). Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Human Reproduction, 28, 2522–2528.
74. Shaker, A., Zosmer, A., & Dean, N. (1996). Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertility and Sterility, 65, 992–996.
75. Schroder, A.K., Schopper, B., Al-Hasani, S., Diedrich, K., & Ludwig, M. (2003). Unilateral follicular aspiration and in-vitro maturation before contralateral oocyte retrieval: a method to prevent ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 110, 186–189.
76. Tan, B.K. & Mathur, R. (2013). Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee. Human Fertility, 16, 151–159.
77. Tang, T., Glanville, J., Orsi, N., Barth, J.H., & Balen, A.H. (2006). The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction, 21, 1416–1425.
78. Tarlatzis, B.C., Fauser, B.C., Kolibianakis, E.M., Diedrich, K., & Devroey, P.; Brussels GnRH Antagonist Consensus Workshop Group. (2006). GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update, 12, 333–340.
79. Tortoriello, D.V., McGovern, P.G., Colon, J.M., Skurnick, J.H., Lipetz, K., & Santoro, N. (1998). “ Coasting ” does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertility and Sterility, 69, 454–460.
80. Tozer, A.J., Al-Shawaf, T., Zosmer, A., Hussain, S., Wilson, C., Lower, A.M., & Grudzinskas, J.G. (2001). Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study. Human Reproduction, 16, 91–95.
81. Tozer, A., Iles, R., Iammarrone, E., Guillott, C., Al-Shawaf, T., & Grudzinskas, J. (2004). The effects of coasting on follicular fl uid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Human Reproduction, 19, 522–528.
82. Tso, L.O., Costello, M.F., Andriolo, R.B., & Freitas, V. (2009). Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2, Art. No.: CD006105. doi:10.1002/14651858. CD006105.pub2.
83. van Wely, M., Kwan, I., Burt, A.L., Thomas, J., Vail, A., Van der Veen, F., & Al-Inany, H.G. (2011). Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews, 2, Art. No.: CD005354. doi:10.1002/14651858.CD005354.pub2.
84. Venetis, C.A., Kolibianakis, E.M., Toulis, K.A., Goulis, D.G., Papadimas, I., & Tarlatzis, B.C. (2011). Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertility and Sterility, 95, 188–196.
85. Yates, A.P., Rustamov, O., Roberts, S.A., Lim, H.Y.N., Pemberton, P.W., Smith, A., & Nardo, L.G. (2011). Anti-Müllerian hormonetailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Human Reproduction, 26, 2353–2362.
86. Youssef, M.A., van Wely, M., Hassan, M.A., Al-Inany, H.G., Mochtar, M., Khattab, S., & van der Veen, F. (2010). Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and metaanalysis. Human Reproduction Update, 16, 459–466.
87. Youssef, M.A., Van der Veen, F., Al-Inany, H.G., Griesinger, G., Mochtar, M.H., Aboulfoutouh, I., et al. (2011a). Gonadotropinreleasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database of Systematic Reviews, 1, Art. No.: CD008046. doi:10.1002/14651858.CD008046.pub3.
88. Youssef, M.A., Al-Inany, H.G., Aboulghar, M., Mansour, R., & Abou-Setta, A.M. (2011b). Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews, 4, Art. No.: CD003719. doi:10.1002/14651858.CD003719. pub3.
89. Youssef, M.A., Al-Inany, H.G., Evers, J.L.H., & Aboulghar, M. (2011c). Intra-venous fl uids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD001302. doi:10.1002/14651858. CD001302.pub2.
90. Yovich, J., Stanger, J., & Hinchliffe, P. (2012). Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reproductive Biomedicine Online, 24, 281–292.
91. Zhu, W.J., Li, X.M., Chen, X.M., & Zhang, L. (2005). Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization. European Journal of Obstetrics, Gynecology and Reproductive Biology, 122, 79–84